Solution: Enhance the effectiveness of anti-epileptic therapy for patients who do not respond to oral medications through regional drug delivery into the brain

Cerebral Therapeutics’ initial clinical program uses a specialized implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose of a proprietary formulation of the anti-epileptic drug valproic acid, called CT001, for which Cerebral Therapeutics has an exclusive license agreement from the University of Colorado. An optimal dose of CT001 is delivered directly into the area of the brain responsible for seizure initiation and propagation.